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Abstract
Purpose—According to current diagnostic criteria, mantle cell lymphoma (MCL) encompasses 
the usual, aggressive variants and rare, nonnodal cases with monoclonal asymptomatic 
lymphocytosis, cyclin D1–positive (MALD1). We aimed to understand the biology behind this 
clinical heterogeneity and to identify markers for adequate identification of MALD1 cases.
Experimental Design—We compared 17 typical MCL cases with a homogeneous group of 13 
untreated MALD1 cases (median follow-up, 71 months). We conducted gene expression profiling 
with functional analysis in five MCL and five MALD1. Results were validated in 12 MCL and 8 
MALD1 additional cases by quantitative reverse transcription polymerase chain reaction (qRT-
PCR) and in 24 MCL and 13 MALD1 cases by flow cytometry. Classification and regression trees 
strategy was used to generate an algorithm based on CD38 and CD200 expression by flow 
cytometry.
Results—We found 171 differentially expressed genes with enrichment of neoplastic behavior 
and cell proliferation signatures in MCL. Conversely, MALD1 was enriched in gene sets related to 
immune activation and inflammatory responses. CD38 and CD200 were differentially expressed 
between MCL and MALD1 and confirmed by flow cytometry (median CD38, 89% vs. 14%; 
median CD200, 0% vs. 24%, respectively). Assessment of both proteins allowed classifying 85% 
(11 of 13) of MALD1 cases whereas 15% remained unclassified. SOX11 expression by qRT-PCR 
was significantly different between MCL and MALD1 groups but did not improve the 
classification.
Conclusion—We show for the first time that MALD1, in contrast to MCL, is characterized by 
immune activation and driven by inflammatory cues. Assessment of CD38/CD200 by flow 
cytometry is useful to distinguish most cases of MALD1 from MCL in the clinical setting. 
MALD1 should be identified and segregated from the current MCL category to avoid 
overdiagnosis and unnecessary treatment.
Introduction
Mantle cell lymphoma (MCL) is a lymphoproliferative disorder of mature B cells 
genetically characterized by the presence of t(11;14)(q13;q32) that juxtaposes the CCND1 
proto-oncogene, encoding for cyclin D1 at chromosome 11q13, to the immunoglobulin 
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heavy chain gene, at chromosome 14q32. As a consequence, deregulated expression of the 
cyclin D1 protein occurs in the mature B-cell compartment (1). While t(11;14)(q13;q32) is 
considered a primary event in the pathophysiology of MCL, at least in part, by deregulating 
cell-cycle progression in the target cells (2), this chromosome translocation does not seem to 
be sufficient for the full transformation of B cells. Different experimental and clinical 
observations suggest that additional oncogenic events are required for the development of 
MCL (3, 4).
Patients with MCLs have a poor prognosis with a median overall survival between 3 and 5 
years (5). However, cases that meet the World Health Organization (WHO) classification 
diagnostic criteria for MCL, but lack its aggressive clinical course, have been reported and 
dubbed as indolent forms of MCL. Such cases are typically characterized by leukemic 
involvement, with or without splenomegaly and absence of lymphadenopathies, for which 
they have also been referred to as nonnodal MCL (6–13). In the last years, we and others 
have proposed that some of these asymptomatic cases may represent a preneoplastic 
condition that could lead to the development of MCL or instead correspond to other types of 
lymphoproliferative disorders with the t(11;14)(q13;q32) (8, 13–15).
In an attempt to gain further insight into the heterogeneous behavior of MCL, we have 
compared a series of classical MCL cases requiring chemotherapy with a homogeneous 
group of asymptomatic individuals harboring a monoclonal expansion of cyclin D1–positive 
mature B cells in the peripheral blood that carry the t(11;14)(q13; q32), in the absence of 
splenomegaly or nodal enlargement due to this process. These cases will be hereafter 
referred to as MALD1 (monoclonal asymptomatic lymphocytosis, cyclin D1–positive), with 
the intention of not to prejudge the neoplastic nature of the process. Of note, these 
asymptomatic cases have ever required or received any treatment after a minimum follow-
up of 26 months (median, 71 months). In this study, we have sought for biologic differences 
between MALD1 and classical MCL, investigating molecular pathways that could be 
enriched in each of these groups. Finally, we selected differentially expressed genes whose 
protein products could be easily analyzed by flow cytometry to develop a useful tool for 
distinguishing MALD1 from classical MCL in routine clinical practice.
Materials and Methods
Patients and samples
Thirty patients studied between 1994 and 2012 who fulfilled the WHO diagnostic criteria for 
MCL and had available cryopreserved peripheral blood samples were included in this study 
(1). From them, 17 were diagnosed with MCL requiring chemotherapy at diagnosis and 13 
corresponded to individuals with monoclonal expansion of mature B cells in peripheral 
blood carrying the t(11;14) (q13;q32) and displaying cyclin D1 overexpression (MALD1). 
Aggressive variants with blastoid or pleomorphic features were excluded from the MCL 
group. Criteria for inclusion in the MALD1 group were as follows: lack of symptoms, no 
enlargement of lymphoid organs related to the process (by physical examination or by 
imaging studies), and follow-up >2 years without requiring any treatment along the whole 
follow-up period. The decision not to treat was based on a number of features including lack 
of constitutional symptoms, absence of progressive or bulky disease, and no severe 
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cytopenia or impaired end-organ function as a consequence of the process. In this setting, a 
watchful waiting approach was adopted. Eight healthy individuals with similar age and 
gender distribution were also included as controls for microarray analyses. This study was 
approved by the Institutional Review Board of the participating institutions, where required, 
and was conducted in accordance with the Declaration of Helsinki.
Histological, immunohistochemical, and immunocytochemical studies
Histologic and immunohistochemical analyses were conducted on formalin-fixed, paraffin-
embedded (FFPE) samples. Immunocytochemical studies were conducted on airdried 
formalin/acetone-fixed peripheral blood smears. Cyclin D1 expression was assessed on 
histologic sections and/or peripheral blood smears of all cases with t(11;14), regardless of 
CD5 expression. In each case, 2 primary antibodies were used: clone P2D11F11 
(Novocastra) and clone SP4 (Neomarkers Inc.). The immunohistochemical analysis of 
SOX11 was conducted with an anti-SOX11 polyclonal antibody (Atlas Antibodies), as 
previously described (9). SOX11 immunostaining on decalcified tissues is not sensitive 
enough so it was not conducted in bone marrow biopsies. The percentage of Ki-67–positive 
cells (clone MIB-1; Dako) was recorded for all available cases.
Morphologic and immunophenotypic analysis of B lymphocytes
Peripheral blood and bone marrow smears were stained with May–Grünwald–Giemsa. 
CD38 and CD200 expression was analyzed in peripheral blood by flow cytometry using a 
mouse IgG1 anti-human CD38 moAb (HB7, BD Biosciences) and a mouse IgG1 anti-human 
CD200 moAb (MRCOX-104, BD Biosciences). The expression of both markers was 
assessed with respect to the mean fluorescence intensity observed in cells labeled with a 
matched isotypic monoclonal antibody. Lymphocytes were gated in the forward and side 
scatter plot to avoid the inclusion of debris, monocytes, and doublets. Regarding CD200 
expression analysis, and to ensure the exclusion of possible contaminating T and natural 
killer cells, the resultant cells were then gated to select CD2+ cells, which were 
electronically excluded (invert gate).
G-banding cytogenetics and FISH
Chromosome analyses were conducted on lymphoid cells from peripheral blood and bone 
marrow 72-hour 12-O-tetradecanoylphorbol-l3-acetate (TPA)-stimulated cultures following 
standard procedures (16). When karyotypes presented with 3 or more cytogenetic 
aberrations, these were classified as complex. FISH analysis was conducted on peripheral 
blood and bone marrow using the IGH/CCND1 dual-color dual fusion translocation probe 
and ATM and TP53 locus–specific probes (Abbott Molecular). Cutoff values were 1%, 10%, 
and 10%, respectively. FISH for IGH/CCND1 was also conducted on FFPE samples (cutoff, 
15%; ref. 17).
Analysis of the major translocation cluster (MTC) breakpoint region of IGH/CCND1 and 
cyclin D1 mRNA isoforms
Analysis of the MTC breakpoint region of IGH/CCND1 was conducted following the 
BIOMED-2 protocol (18). Positive cases were sequenced by capillary electrophoresis. 
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Sequences were aligned to previously reported MTC region sequences using ClustalW. 
Identification of the IGHJ segments involved in the translocation and alignment to 
previously reported sequences were conducted using the IgBlast public server. CCND1 
mRNA isoforms were assessed as previously described (19).
Mutational studies of immunoglobulin heavy chain V genes
The mutational status of IGHV genes was assessed as previously described (20). Samples in 
which <2% of base pairs differed from those of the consensus sequence were considered 
unmutated.
Microarray analyses
Microarray analyses were conducted on RNA isolated from B lymphocytes obtained from 
peripheral blood by means of immunomagnetic bead selection (B-cell isolation kit II, 
Miltenyi Biotec GmbH) that yielded purities of ≥90% as assessed by flow cytometry (CD19 
APC, clone SJ25C1, BD Biosciences). In cases carrying the t(11;14)(q13;q32) translocation, 
the percentage of pathologic cells as assessed by flow cytometry was ≥80% of total B 
lymphocytes.
Microarray expression profiles were obtained using the Affymetrix Human Exon 1.0 ST 
arrays (Affymetrix). Raw data were normalized to a logarithmic transcript level using the 
robust multichip average (RMA; ref. 21) and core annotations, obtaining a total of 18,708 
transcript clusters. Normalized data were then filtered to avoid noise created by 
nonexpressed transcript clusters. This filtering was conducted in 2 steps: first, only 
transcripts with intensity signal >10% of the mean of all intensities of the studied groups 
were selected; then, those with a variance >80% were considered for further analysis, which 
lead to 3,479 transcript clusters. Linear models for microarray (LIMMA; ref. 22), a 
moderated Student t test, was used for detecting differentially expressed genes between 
groups. Correction for multiple comparisons was conducted using false discovery rate 
(FDR), and only genes with an adjusted P < 0.05 were considered significant. Hierarchical 
cluster analysis was also conducted to see how samples and genes aggregated. All data 
analysis was conducted in R (version 2.15.0) with bioconductor (23) and aroma.affymetrix 
packages (version 2.7.0; ref. 24). Functional analysis was conducted using the Ingenuity 
Pathway Analysis (IPA version 8.5; ref. 25) and gene set enrichment analysis (GSEA) 
computational method (26). The gene sets with P < 0.05 and FDR < 0.2 were considered to 
be enriched and potentially relevant. The functional heat map was generated by aggregating 
results of the GSEA and IPA pathway analyses into common categories. The mean of gene 
expression values belonging to each pathway was taken as the representative value for each 
sample. Microarray raw data have been deposited in the Gene Expression Omnibus (GEO) 
database with series accession number GSE45717 (27).
Gene expression analysis by quantitative RT-PCR
cDNAs were prepared from 1 μg RNA using the High-Capacity cDNA Archive Kit (Applied 
Biosystems). The following genes were analyzed in an ABI Prism 7900HT instrument 
(Applied Biosystems): CCND1 (Hs00277039_m1), BTLA (Hs00699198_m1), CD200 
(Hs01033303_m1), MEF2C (Hs00231149_m1), PON2 (Hs00165563_m1), HMGB3 
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(Hs00801334_m1), SOX11 (Hs00846583_s1), CD38 (Hs00233552_m1), GAB2 
(Hs00373045_m1), LGALS3BP (Hs00174774_m1), MYO6 (Hs00192265_m1), NEO1 
(Hs00170143_m1), TXN (Hs00828652_m1), PTK2 (Hs00178587_m1), and ADAMS28 
(Hs00248020_m1) along with β-glucuronidase (GUSB; part number 4326320E) using 
specific commercially available TaqMan gene expression assays. Relative expression levels 
were calculated with the 2−ΔΔCt method using GUSB as endogenous control.
Generation of the CD38/CD200 classifier
The Classification and Regression Trees (CART) strategy was used to generate a 
classification algorithm based on CD38 and CD200 expression assessed by flow cytometry. 
This algorithm was built using R with the Rpart package. Rpart is a nonparametrical 2-step 
method, which can be easily represented as a decision tree graph. The first step finds the 
single variable that best splits the cases into 2 groups, on the basis of the minimum Gini 
index, an estimation based on all possible splits using all available variables. All possible 
cutoff values for all variables considered in the model are tested to select the split that most 
decreases the Gini index at the first node. The cases are then assigned to each newly 
generated node and this process is recursively applied to each of the descendant nodes, until 
no improvement can be achieved. In the second step, the resulting full tree is trimmed back 
using a cross-validation procedure (28). The 95% confidence interval (CI) of the proportions 
of correctly classified patients by the proposed decision tree were computed using methods 
with continuity correction (29).
Statistical analyses
Comparisons were conducted using the Mann–Whitney U test for continuous and ordinal 
variables and the Fisher exact test for categorical variables. P < 0.05 from 2-sided tests was 
considered to indicate statistical significance. The probability of survival was assessed with 
actuarial life tables, and 95% CIs were calculated. The SPSS 16.0 statistical software 
package (SPSS) was used for all statistical analyses.
Results
Clinical presentation, laboratory findings, and follow-up of MCL and MALD1 cases
The main clinical and laboratory features at diagnosis are detailed in Table 1 and 
Supplementary Tables S1 and S2. The reason for referral was different between the 2 
groups: while most patients with MCL presented with palpable lymphadenopathies (14 of 
17), 12 of 13 MALD1 cases were referred because of abnormal routine peripheral blood 
tests, including lymphocytosis (7 of 13 cases) and atypical lymphocytes in peripheral blood 
smears with a normal lymphocyte count (5 of 13 cases). In the remaining case, referral was 
due to a single submandibular lymphadenopathy related to an inflammatory condition 
(sarcoid granulomatous reaction). In most MALD1 cases, the morphology of abnormal 
lymphocytes in blood smears was similar to that of typical chronic lymphocytic leukemia 
(CLL) and monoclonal B-cell lymphocytosis (MBL) without smudge cells, whereas in MCL 
cases, the atypical lymphocytes displayed more irregular nuclear contours, as previously 
reported (30). The absolute lymphocyte count at presentation ranged from 3.1 to 12.2 × 
109/L in MALD1 cases and from 0.7 to 69 × 109/L in patients with MCL. MALD1 
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lymphocyte counts over time have been plotted in Supplementary Fig. S1. All MALD1 
individuals and most patients with MCL (69%) showed peripheral blood involvement by 
flow cytometry, with percentages of abnormal lymphocytes ranging from 11% to 76% in 
MALD1 cases and from 0% to 86% in patients with MCL. There were no significant 
differences between MALD1 (5/13) and MCL (6/14) cases regarding CD23 expression, nor 
in the intensity of surface immunoglobulin expression. Interestingly, the moderate/high 
intensity of surface immunoglobulin expression in all MALD1 cases (13 of 13) was different 
to that reported in MBL with typical CLL phenotype, usually negative or weakly positive 
(31).
MCL cases showed lower hemoglobin level (P = 0.012), with higher erythrocyte 
sedimentation rates (ESR) and β2- microglobulin levels than MALD1 cases (P = 0.001 for 
both variables). Regarding disease stage and both the IPI and MIPI prognostic indexes, no 
differences were observed between MCL and MALD1 cases. Of note, 69% and 54% of 
MALD1 cases were assigned to the IPI and MIPI intermediate- or high-risk groups, 
respectively. Overall survival of patients with MCL at 2 and 5 years was 88% and 73%, 
respectively; conversely, all MALD1 individuals remain alive and have not received any 
treatment with a median follow-up of 71 months (range, 26–186 months).
MALD1 and MCL show distinct histological features
The main histologic and immunohistochemical features of both groups are detailed in Table 
1 and Supplementary Table S1. In patients with MCL, the involvement of different organs 
was apparent in hematoxylin and eosin (HE)- stained slides due to the disruption of normal 
architecture, and it was confirmed by immunohistochemistry (IHC) and FISH techniques. 
Tissue samples of secondary lymphoid organs were available from 6 MALD1 cases (upper 
and lower gastrointestinal tract samples in all 6 cases and lymph nodes in two of them). 
Noteworthy, the presence of the abnormal lymphoid population would not have been 
suspected by histology alone, in the absence of previous flow cytometry and/or cytogenetic 
data. The immunohistochemical analysis of secondary lymphoid organs from MALD1 cases 
identified cyclin D1–positive small lymphoid cells with predominantly round nuclei in 5 of 
6 cases. The cyclin D1–positive cells were mainly located in the lymphoid aggregates 
lacking germinal centers and in the mantle zones of secondary follicles, without any 
significant expansion of these areas, thus displaying a so-called in situ histologic pattern. 
Bone marrow biopsies were available from the aforementioned 6 MALD1 cases. 
Immunohistochemical analysis revealed the presence of a cyclin D1–positive interstitial 
lymphoid infiltrate in all of them, which was usually overlooked in HE sections. Only 
SOX11 and Ki-67 expression were significantly different between MCL and MALD1 
groups (P < 0.001 and P = 0.002, respectively). SOX11 was negative in the 5 MALD1 cases 
in which colonization of secondary lymphoid organs by cyclin D1–positive cells could be 
proven. On the other hand, 11 of 11 MCL cases showed strong SOX11 nuclear expression, 
along with a higher percentage of Ki-67–positive cells.
MALD1 shares diagnostic cytogenetic and molecular features with MCL
The main cytogenetic and molecular features are detailed in Table 1 and Supplementary 
Table S2. All MALD1 and MCL cases displayed a t(11;14)(q13;q32) by G-banding 
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cytogenetics and/or FISH. qRT-PCR analysis confirmed increased CCND1 mRNA 
expression levels in MALD1 and MCL samples when compared with healthy controls, and 
these higher levels correlated with cyclin D1 protein overexpression, as detected by IHC. In 
0 of 12 MALD1 and 1 of 7 MCL cases, the truncated CCND1 mRNA isoform, associated to 
shorter survival, was identified (19). Analysis of IGH/CCND1 gene rearrangements at the 
CCND1 MTC breakpoint region showed a similar percentage of events involving this region 
in MCL and MALD1 cases. There was a difference in size between the PCR product 
obtained from MALD1 cases (median size of the PCR product, 269 bp; range, 202–288) and 
that from patients with MCL (median size, 212 bp; range, 207–213). However, the structural 
similarities between MALD1 and MCL breakpoints suggest that the mechanisms leading to 
the IGH/CCND1 translocation in both groups could not differ in their basis (Supplementary 
Table S3; ref. 32). Finally, all MALD1 cases analyzed showed clonal IGHVDJ gene 
rearrangements.
MALD1 cells are involved in immune reactions and show evidence of transit through the 
germinal center
As a part of the routine staging protocol for MCL, upper and lower endoscopy was 
conducted in most cases (33). A follicular chronic gastritis associated with Helicobacter 
pylori infection was detected in gastric mucosa biopsies from three MALD1 subjects. 
Immunohistochemical analysis of these samples revealed numerous cyclin D1–positive 
lymphoid cells in the follicular mantles of the acquired MALT (Fig. 1A–C). FISH analysis 
confirmed the presence of t(11;14) (q13; q32) in these cells, and molecular analysis showed 
the same IGH clonal rearrangements as those found in the other tissues studied (data not 
shown). Biopsies taken after routine antibiotic treatment for the gastric infection revealed a 
slight residual atrophy without evidence of bacilli and, more importantly, complete absence 
of lymphoid infiltrates (Fig. 1D–F). In contrast, in a MCL patient with concurrent H. pylori 
infection and tumor infiltration, the antibiotic treatment eliminated the H. pylori but not the 
cyclin D1–positive tumor cells.
The above findings suggested that despite their clonal nature, MALD1 cells could actively 
participate or be recruited to antigen-driven immune reactions and would disappear from the 
involved organ when the antigen is cleared. Thus, we next analyzed whether there was any 
molecular evidence supporting the involvement of MALD1 cells in immune reactions, by 
assessing the presence of somatic hypermutation events in the IGHV genes. Analysis of the 
mutational status of the IGHV genes could be conducted in 12 of 13 MALD1 individuals 
and in 13 of 17 patients with MCL. All MALD1 cases showed mutated IGHV genes, 
whereas only 4 of 13 patients with MCL had somatic mutations (P < 0.001; Table 1 and 
Supplementary Table S2). No significant bias in the usage of VH segments was observed in 
any of the 2 groups. The occurrence of somatic hypermutation events in IGHV genes all 
MALD1 cases indicates that MALD1 lymphocytes may have transited through the germinal 
center. On the other hand, the percentage of somatic hypermutations in the patients with 
MCL of the present study is 31%, in agreement with previous series (34–36). Remarkably, 
analysis of the sequences of VH segments in sequential samples of 3 MALD1 individuals 
showed no evidence of acquired (ongoing) somatic hypermutation events from the time of 
diagnosis (data not shown). This finding suggests that transit through the germinal center in 
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MALD1 lymphocytes probably occurred before their clonal expansion, an observation that 
contrasts with the pregerminal center origin postulated for MCL (15, 34).
Gene expression profile of clonal B cells reveals significant biological differences between 
MALD1 and MCL
To better understand the basis for possible biologic differences between MCL and MALD1, 
we analyzed the gene expression profiles of enriched B-cell fractions isolated from 
peripheral blood of 5 MALD1 subjects, 5 patients with MCL, and 8 healthy individuals. 
Unsupervised hierarchical clustering of gene expression data revealed robust differences 
between MALD1 and MCL B cells (Fig. 2A). When compared with normal peripheral blood 
B cells from healthy individuals, MALD1 and MCL clustered together, indicating that 
peripheral blood B cells from both groups share significant differences with normal B cells 
(Fig. 2B). Supervised analysis between MALD1 and MCL samples identified a gene 
signature composed of 174 differentially expressed transcript clusters (171 genes). This 
signature clustered together MALD1 and normal B cells (Fig. 2C, Supplementary Table S4). 
The microarray results were confirmed by qRT-PCR analysis of a subset of top differentially 
expressed genes (Supplementary Fig. S2). Validation was conducted in the same 10 cases (5 
MCL and 5 MALD1) used for microarray analyses. The 20 remaining cases (12 MCL and 8 
MALD1) were used as a validation set.
The MALD1/MCL gene signature included CD38 [log fold change (logFC) = 1.51; adj. P = 
0.024], upregulated in MCL, and CD200 (logFC = 2.04; adj. P = 0.005), upregulated in 
MALD1, 2 flow cytometric markers commonly used in the study of peripheral blood 
lymphocytosis. Unlike previous reports (9, 37), SOX11 was not part of the MALD1/MCL 
gene signature, even though statistically significant differences in SOX11 mRNA expression 
between MALD1 and MCL were detected by qRT-PCR (Supplementary Fig. S2). This 
apparent discordance can be explained by the differences between the probe sets included in 
the Human Exon 1.0 ST array (used in this study), and the 3′IVT array probe sets (HGU133 
Plus2 arrays) used in those studies (Supplementary Fig. S3).
Pathway analysis using the IPA tool indicated that the MALD1/MCL gene signature was 
significantly enriched in genes involved in 2 main biologic processes, namely inflammatory 
responses in MALD1, and cell growth and proliferation in MCL (Fig. 3, Supplementary 
Table S5). These differences were confirmed and further refined using the GSEA tool. Many 
cancer-related signatures (cell cycle and proliferation, Myc deregulation, and self-renewal), 
as well as gene signatures associated to cyclin D1/Cdk4 activation, were specifically 
enriched in MCL. In addition, we observed a significant enrichment for DNA damage repair 
pathways (ATM and global genomic nucleotide excision repair pathways). Both cell cycle 
and DNA damage repair–related pathways have been previously invoked in the pathogenesis 
of MCL (28, 29). In contrast, MALD1 gene expression profiles were highly enriched in gene 
sets related to inflammatory responses, B-cell activation, immunoregulatory interactions, 
cytokine signaling, and lymphocyte/cell adhesion, and migration, suggesting that 
inflammatory cues drive the biology of these cells, as also supported by the histologic data 
(Fig. 1). Thus, gene expression analysis identified significant differences in selected gene 
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expression programs between MCL and MALD1 B cells, in concordance with the clinical 
and histologic evidence.
Surface CD38/CD200 expression by flow cytometry is useful to discriminate between 
MALD1 and MCL
Among other specific surface molecules found to be differentially expressed between 
MALD1 and MCL, we chose to further validate CD200 and CD38 on peripheral blood 
samples, given their widespread use in routine phenotypic panels for the study of 
lymphocytosis (30). Particularly, CD38 was highly expressed in patients with MCL but not 
in MALD1 cases, an observation further confirmed by qRT-PCR analysis (P = 0.007; Fig. 
4A). Flow cytometric data on CD38 surface expression in peripheral blood were available in 
37 cases (11 of 17 MCL and 13 of 13 MALD1 from the original series, and 13 additional 
MCL cases). In agreement with the molecular data, patients with MCL displayed a 
significantly higher percentage of CD38+ B cells (median, 89%; range, 0%–100%) than that 
observed among MALD1 individuals (median, 14%; range 0%–35%; P < 0.001; Fig. 4B and 
C and Supplementary Table S2).
Regarding CD200, it was highly expressed in MALD1 cases but not in patients with MCL, 
and this observation was confirmed by qRT-PCR (P < 0.001; Fig. 4D). CD200 surface 
expression was available in peripheral blood B-cell lymphocytes of 27 cases (2 of 17 MCL 
and 12 of 13 MALD1 from the original series, and 13 additional MCL cases; Fig. 4E and F, 
Supplementary Table S2). In agreement with the qRT-PCR data, all MCL cases showed 
very low or absent CD200 expression (median, 0%; range, 0%–5%), whereas the majority of 
MALD1 cases analyzed showed a higher percentage of CD200+ B cells (median, 24%; 
range, 0%–95%; P < 0.001). These observations suggest that flow cytometric analysis of 
CD38 and CD200 expression on clonal B cells from peripheral blood samples is useful for 
the distinction between MCL (CD38+/CD200−) and MALD1 cases (CD38−/CD200+). On 
the basis of these findings, we designed a classifier to discriminate between both entities in 
the clinical setting. We generated a CART based on 2 splits, the first one, CD38 ≥ 40%, 
classifies patients as MCL, whereas the second split, CD200 ≥ 2%, assigns the MALD1 
cases (Fig. 5A). We have considered a third non-classified category, encompassing cases 
with low values for both markers. This algorithm correctly classified 88% (21 of 24; 95% 
CI, 67%–97%) of the patients with MCL and 85% (11 of 13; 95% CI, 54%–97%) of the 
MALD1 cases (Fig. 5B and Supplementary Table S6), the rest of the cases remaining as 
non-classified. Of note, none of the cases was classified in the opposite category. To better 
characterize the non-classified cases (2 MALD1 and 3 MCL), we analyzed whether SOX11 
expression assessed by qRT-PCR could help in classifying these cases. The 2 MALD1 
individuals (MALD1-5 and MALD1-10) displayed low levels of SOX11 expression, as 
expected. On the other hand, in the 2 MCL cases (MCL-1 and MCL-14) with available 
sample, SOX11 expression was also low and showed mutated IGHV genes. Interestingly, 
when analyzing the whole series, mutated IGHV cases showed statistically significant higher 
levels of SOX11 expression than unmutated cases (P = 0.001). These differences were 
maintained when considering only patients with MCL (P = 0.027).
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Discussion
On the basis of current diagnostic criteria, MCL encompasses a spectrum of cases ranging 
from the usual, aggressive variants to rare, nonnodal cases that remain asymptomatic for 
many years, even without treatment (6–13, 38). This clinical heterogeneity probably reflects 
incomplete knowledge of the MCL pathogenesis, with the resulting diagnostic 
oversimplification. In fact, current prognostic indexes for MCL (IPI, MIPI; refs. 39, 40) are 
not suitable for MALD1 cases, as they would label some of them as intermediate or even 
high-risk MCL, mainly due to the presence of leukocytosis and/or to advanced age, despite 
their benign clinical course (34). It has been speculated that some of the asymptomatic cases 
represent a preneoplastic condition that would either lead to the development of MCL or 
remain stable lifelong (7–13, 15, 41, 42). It is even possible that some asymptomatic cases 
could belong to a different biologic category sharing only some of the diagnostic features of 
MCL (8, 13, 15). Therefore, it is crucial to gain further insight into the molecular differences 
between MCL and MALD1 and to find biologic markers that, in addition to clinical 
presentation, allow identifying MALD1 cases and avoid their overtreatment.
While previous series dealing with this topic are rather heterogeneous (7, 9, 10, 12, 13), we 
have attempted to characterize a homogeneous group of cases (MALD1) presenting without 
splenomegaly or nodal enlargement due to the disease and never requiring treatment despite 
a long follow-up (median, 71 months). This group was compared with a cohort of classical 
patients with MCL, from which aggressive histologic variants had been excluded to avoid 
confounding factors related to disease progression. Despite their clonal nature and the 
presence of t(11;14)(q13;q32), MALD1 cells lack several common features of MCL B 
lymphocytes and are defined by a paucity of genomic abnormalities, a low proliferative 
fraction, and their recruitment to active inflammatory/immune foci. Moreover, the normal 
architecture was preserved in all lymphoid organs analyzed from MALD1 individuals in our 
series. Characteristically, MALD1 cells have cyclin D1 overexpression and locate only to 
normal lymphoid structures (i.e., mantle zones), as normal B cells do in immune reactions. 
In this regard, we have shown for the first time that in those MALD1 cases with H. pylori–
associated chronic gastritis, cyclin D1–positive cells disappear from the gastric mucosa after 
antigen elimination by antibiotic therapy (Fig. 1) whereas these cells persist in MCL cases. 
This different behavior could reflect that presence of MALD1 cells in the gastric mucosa is 
dependent on the preservation of their homing compartment (acquired MALT). In 
agreement with these observations, we have also first shown that MALD1 expression 
profiles are highly enriched in gene sets related to immune activation and inflammatory 
responses, indicating that inflammatory cues drive the biology of these cells (Fig. 3, 
Supplementary Table S5). In contrast, gene expression analysis only detected enrichment of 
signatures associated with neoplastic behavior and proliferation in MCL cases. Consistent 
with the above observations, MALD1 B lymphocytes showed features of antigen-
experienced cells, namely, the presence of IGHV hypermutations, as well as a replication 
history (determined by the abundance of IgK-deleting rearrangement excision circles; 
KREC assay, data not shown; ref. 43), that indicate occasional transit through the germinal 
center. Notably, the VH segment sequences in consecutive samples of 3 MALD1 individuals 
showed no evidence of ongoing somatic hypermutation events from the time of diagnosis, 
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strongly suggesting that transit through the germinal center of MALD1 lymphocytes 
probably occurred before their clonal expansion. These observations contrast with the 
pregerminal center origin postulated for most MCL (1).
It is well known that single genetic events are not sufficient for malignant transformation 
(44, 45). Isolated genetic lesions like t(11;14) should not be used as the only criterion to 
support the diagnosis of lymphoma. In fact, despite being the primary event in the 
pathogenesis of MCL, additional oncogenic events are known to be required for malignant 
transformation (3, 46). While the biologic and clinical behavior of MALD1 is far from that 
expected in neoplastic cells, we have shown that MALD1 lymphocytes carry genetic 
abnormalities unseen in normal B cells as t(11;14) and clonal expansion. This could 
eventually prime them for neoplastic transformation in the proper biologic context. Given 
the exceptionality and limited knowledge of preneoplastic lesions in the lymphoid system, 
we cannot rule out that MALD1 may act in the long term as a precursor of MCL, similar to 
what has been reported for MBL and CLL (31, 47–49). In this regard, MALD1 cases would 
be related to the fraction (20%–40%) of MCL cases with hypermutated IGHV genes, which 
typically show nonnodal disease at presentation, an indolent clinical course, and a long 
disease-free survival (35, 36). Finally, according to our results, another possibility that 
cannot be excluded is that MALD1 cases might instead belong to a distinct disease category, 
biologically unrelated to MCL.
Several groups have addressed the need for reliable markers to identify cyclin D1–positive 
cases not requiring early treatment. Among them, SOX11, for which an oncogenic role has 
been recently proposed, has been the most widely explored (50, 51). Lack of SOX11 
expression, alone or in combination with other genes, has been proposed as a candidate 
marker with conflicting results (9, 13, 52). The limitation of these markers is that, as the 
majority of asymptomatic cases only show peripheral blood expression, the assessment must 
be made by qRT-PCR in isolated B cells from peripheral blood. As these techniques are not 
readily implementable in all laboratories, one of the aims of our study was to identify 
differentially expressed genes between MALD1 and MCL, providing the basis for a simple 
routine diagnostic test. Among the differentially expressed and validated genes in our study, 
we selected CD38 and CD200 because antibodies for their proteins are already used in 
current diagnostic flow cytometric panels for mature B-cell lymphoproliferative processes 
(53).
CD38 is an ectoenzyme with an unclear function in B cells (54). CD38 expression is a well-
recognized prognostic factor in CLL and it has also been suggested as a marker that partially 
differentiates nodal from nonnodal MCL (7). In our study, CD38 expression was found to be 
consistently high in MCL whereas low or absent in MALD1 cases. It has been proposed that 
CD38 may favor neoplastic B-cell survival by engaging CD31, an adhesion molecule 
expressed by endothelial cells (55). In MALD1 cases, low CD38 expression may minimize 
the interaction of MALD1 B cells with CD31-expressing microvessels, thus attenuating 
clonal B-cell accumulation.
CD200 is an Ig superfamily member frequently upregulated in CLL and has been proposed 
as a useful marker for the differential diagnosis between CLL and MCL (56, 57). CD200 
Espinet et al. Page 12
Clin Cancer Res. Author manuscript; available in PMC 2015 July 02.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
was found to be consistently low or absent in all MCL but highly expressed in most MALD1 
cases. CD200 binds to CD200R, an inhibitory receptor expressed by both lymphoid and 
myeloid cells. It is tempting to speculate that an increased frequency of inhibitory signals 
emerging from CD200–CD200R interaction attenuates the proliferation of MALD1 B cells, 
thus contributing to the asymptomatic behavior of MALD1 cases. Conversely, reduced 
CD200 expression by conventional MCL may contribute to its more aggressive biologic 
behavior.
Despite the low prevalence of MALD1 cases, we have generated an algorithm based on 
CD38 and CD200 expression that correctly assigned most MALD1 and MCL cases; more 
importantly, such algorithm did not classify any of these cases in the opposite category. 
SOX11 expression by qRT-PCR did not improve the classification obtained by the 
algorithm. Our results indicate that a combined analysis of CD38 and CD200 by flow 
cytometry could be used to discern between MALD1 and MCL. However, as some cases 
show close values to the cutoff of both markers, these parameters should be considered in 
the whole clinical and biologic context.
In summary, we have studied a very homogeneous group of untreated asymptomatic 
individuals with monoclonal cyclin D1–positive lymphocytosis and a long follow-up 
(MALD1). We have shown for the first time that these cases are characterized by immune 
activation and driven by inflammatory cues. This is in contrast with the biology of overt 
MCL and translates into a benign clinical behavior. Although more studies with a larger 
number of cases are needed, our results suggest that combined flow cytometric assessment 
of CD38 and CD200 expression provides a simple and useful tool to distinguish most 
MALD1 cases from patients with MCL in the clinical setting, which may contribute to avoid 
overdiagnosis and unnecessary treatment of subjects with MALD1.
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Translational Relevance
This article shows for the first time that monoclonal asymptomatic lymphocytosis, cyclin 
D1–positive (MALD1), in contrast to typical mantle cell lymphoma (MCL), is 
characterized by immune activation and is driven by inflammatory cues. This distinct 
biology translates into a benign clinical course. It also shows that assessment of CD38 
and CD200 by flow cytometry is useful to distinguish most cases of MALD1 from MCL 
in the clinical setting. According to these results, most of the MALD1 cases can be 
clearly identified and segregated from the current MCL category avoiding overdiagnosis 
and unnecessary treatment.
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Figure 1. 
MALD1 participate in immune reactions. Top, chronic gastritis in a MALD1 case. A, 
lymphoid follicles formation in the lamina propria (HE; ×20). B, main image: numerous 
lymphoid cells overexpressing cyclin D1 in the mantle zone (IHC; ×20); inset: boundary 
between the germinal center and mantle zone (IHC; ×700). C, abundant H. pylori in the 
lumen of the gastric pits (Giemsa; ×900). Bottom, posttreatment study of the same case. D, 
mild mucosal atrophy without inflammation (HE; ×40). E, absence of lymphoid cells 
expressing cyclin D1 (IHC; ×40). F, absence of H. pylori in the lumen of the gastric pits 
(Giemsa; ×900).
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Figure 2. 
Gene expression analysis of CD19+ peripheral blood B cells reveals significant differences 
between MALD1 and MCL. A, unsupervised hierarchical clustering of the gene expression 
profiles (GEP) from healthy controls (HCTRL), MALD1, and MCL cases. B, unsupervised 
hierarchical clustering of GEP from MALD1 and MCL cases separates the 2 entities based 
on distinct gene signatures. C, heatmap showing the results of the supervised analysis using 
genes differentially expressed between MALD1 and MCL cases. The list of genes appearing 
in the heatmap is detailed, in order of appearance, in Supplementary Table S4.
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Figure 3. 
Biologic pathways differentiate MALD1 and MCL cells. Functional heatmap showing 
relative enrichment of biologic pathways in the 2 groups. This heatmap was generated by 
aggregating results of the GSEA and IPA analyses in common categories and taking the 
mean of gene expression in each pathway as the representative value for each sample.
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Figure 4. 
Differences in CD38 and CD200 surface protein and mRNA expression between MALD1 
and MCL cases. A, box plots representing the mRNA expression levels of CD38 in the 2 
groups, as determined by qRT-PCR and expressed in relative units (Mann–Whitney test). B, 
box plots depicting the distribution of CD38-positive cells within the clonal peripheral blood 
B-cell population in the 2 groups (Mann–Whitney test), as assessed by flow cytometry. C, 
representative examples of flow cytometry analysis of CD38 surface expression in 
representative MALD1 (top) and MCL (bottom) peripheral blood B cells (CD19+, CD5+, 
highlighted in red on the right). The mean fluorescence intensity is used as a parameter to 
plot the levels of CD38 expression (histograms). D, box plot representation of CD200 
mRNA total levels in MALD1 and MCL cases and expressed in relative units (Mann–
Whitney test). E, box plots depicting the distribution of CD200-positive cells within the 
clonal peripheral blood B-cell population in the 2 groups (Mann–Whitney test), as assessed 
by flow cytometry. F, representative examples of flow cytometric analysis of CD200 surface 
expression in representative MALD1 (top) and MCL (bottom) peripheral blood B cells 
(highlighted in red) using the mean fluorescence intensity as a parameter (histograms).
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Figure 5. 
CD38 and CD200 surface expression are helpful to discriminates between MCL and 
MALD1. A, resulting decision tree graph based on CD38 and CD200 expression assessed by 
flow cytometry classifies cases in 3 groups: MCL, MALD1, and non-classified. B, graphical 
distribution of studied cases depicted in blue (MALD1) and orange (MCL). Blue box 
corresponds to MALD1 assigned group by the tree, orange box corresponds to MCL 
assigned group, and gray box to the non-classified group.
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Table 1
Summary of clinical and pathologic characteristics, as well as clonal diagnostic markers, of the cases included 
in the present study
Variable MCL (n = 17) MALD1 (n =13) P
Age ≥ 60 y 11/17 (65) 7/13 (54) 0.711
Males 7/17 (41) 7/13 (54) 0.713
B symptoms 4/17 (24) 0/13 (0) 0.113
Poor performance status (ECOG ≥ 2) Splenomegaly 3/17 (18) 0/13 (0) 0.238
7/14 (50) 0/13 (0) 0.051
Hemoglobin level, g/L 117 (67–163) 155 (94–172) 0.012
Platelet count, ×109/L 183 (50–402) 200 (114–400) 0.391
Leukocyte count, ×109/L 8.5 (3.8–87) 12.1 (7.0–18.9) 0.286
Lymphocyte count, ×109/La 3.6 (0.7–69) 6.5 (3.1–12.2) 0.187
Albumin < 30 g/L 1/17 (6) 0/13 (0) 1
ESR, mm 39 (7–140) 12 (2–31) 0.001
LDH level ≥ 450 IU/L 3/17 (19) 1/13 (8) 0.613
β2-Microglobulin level ≥ 2.1 mg/L 12/17 (70) 1/13 (8) 0.001
Monoclonal component 3/17 (18) (IgGL, IgMK) 2/13 (15) (IgGL, IgMK) 1
Advanced stage (Ann Arbor III–IV) 15/17 (88) 13/13 (100) 0.492
Extranodal involvement
 ≤1 10/17 (59) 10/13 (77) 0.440
 >1 7/17 (41) 3/13 (23)
Bone marrow infiltration (histology and/or cytology)
IPI
13/16 (81) 10/10 (100) 0.262
 Low risk 7/17 (41) 4/13 (31) 0.356
 Low-intermediate risk 2/17 (12) 8/13 (61)
 High-intermediate risk 5/17 (29) 1/13 (8)
 High risk 3/17 (18) 0/13 (0)
MIPI
 Low risk 10/17 (59) 6/13 (46) 0.872
 Intermediate risk 1/17 (6) 6/13 (46)
 High risk 6/17 (35) 1/13 (8)
Diffuse pattern in secondary lymphoid organs 7/14 (50) 0/6 (0) 0.106
Cyclin D1 expression (IHC and/or ICC) 17/17 (100) 13/13 (100) 1
CD5 expression (IHC and/or FC) 16/16 (100) 10/13 (77) 0.070
SOX11 expression (IHC) 11/11 (100) 0/5 (0) <0.001
Percentage of Ki-67–positive cells in secondary lymphoid organs (IHC) 20 (10–35) 5 (3–5) 0.002
t(11;14) alone (CGC) 2/8 (25) 5/13 (39) 0.183
Complex karyotype (CGC) 4/15 (50) 1/13 (8) 0.333
TP53 deletion (FISH) 3/14 (21) 1/13 (8) 0.596
ATM deletion (FISH) 4/14 (29) 0/13 (0) 0.098
MTC rearrangement (PCR) 4/17 (24) 5/13 (39) 0.443
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Variable MCL (n = 17) MALD1 (n =13) P
IGHV hypermutated 4/13 (31) 12/12 (100) <0.001
SOX11 expression (qRT-PCR) 430 (0–1201) 10 (0–100) 0.003
NOTE: Results are expressed as cases/total cases (%) for the categorical variables and median (range) for continuous variables. For further details, 
see Supplementary Tables S1 and S2. Parameters showing statistically significant differences between both groups are shown in bold.
Abbreviations: CGC, conventional G-banding cytogenetics; ECOG, Eastern Cooperative Oncology Group; ESR, erythrocyte sedimentation rate; 
FC, flow cytometry on peripheral blood; ICC, immunocytochemistry on peripheral blood; IHC, immunohistochemistry on secondary lymphoid 
organs and/or bone marrow; IPI, international prognostic index; LDH, lactate dehydrogenase; MIPI, MCL international prognostic index.
aNormal values for lymphocyte counts in the hospitals submitting cases ranged from 1 × 109/Lto1.5 × 109/L for minimum values and from 3 × 
109/L to 5 × 109/L for maximum values.
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